MARINA SALUD SA

Their core work

Marina Salud SA is a private healthcare provider based in Denia-Alicante, Spain, that engages in EU-funded research as a clinical end-user and validation partner. Their role in H2020 projects is to provide real-world hospital and care-center settings where research tools are tested, refined, and validated against actual patient workflows. They have contributed to projects addressing two pressing challenges in modern healthcare: protecting patient data under GDPR in clinical environments, and applying artificial intelligence to personalize health monitoring and support clinical decisions. For research consortia, they offer what most technology developers lack — direct access to clinical practice, patient populations, and the institutional knowledge needed to make digital health tools actually work at the bedside.

What they specialise in

How they've shifted over time

Marina Salud's H2020 track record is short — two projects between 2019 and 2024 — so the evolution is narrow but readable. Their entry point was regulatory and security compliance: ProTego addressed data-protection risk in clinical settings, a largely defensive and operational concern. By the time iHELP began in 2021, the focus had shifted toward proactive intelligence — using AI to personalize care and support clinical decisions, with a specific lens on cancer. The direction of travel is from compliance-driven digitalization toward AI-augmented clinical practice.

Marina Salud is moving from passive compliance participation toward active clinical AI validation, making them an increasingly relevant partner for health data science and oncology-focused digital health projects.

How they like to work

Marina Salud has never led an H2020 project — both participations are as a consortium partner, which is consistent with the role of a clinical end-user rather than a research driver. Across just two projects they have built a network of 27 partners in 11 countries, suggesting they join mid-to-large consortia rather than tight bilateral collaborations. This pattern — joining as a validated clinical site rather than as a technical contributor — tells potential partners that Marina Salud brings institutional access and real-world testing capacity, not research infrastructure or IP development.

Despite only two projects, Marina Salud has connected with 27 distinct consortium partners spread across 11 countries, reflecting participation in well-networked, multi-stakeholder European health research consortia. Their geographic reach is genuinely European, though no dominant country cluster is visible from the available data.

What sets them apart

Marina Salud occupies a specific and hard-to-replace niche: a private Spanish healthcare provider willing to serve as a clinical validation site in competitive EU research projects. Unlike university hospitals or public health systems, private providers of their type can move faster on partnership agreements and offer direct access to defined patient populations — including, based on iHELP, oncology patients. For any consortium developing digital health tools that need real-world clinical testing in a Mediterranean healthcare context, Marina Salud offers both the institutional legitimacy and the operational access that pure technology partners cannot provide.

Highlights from their portfolio

• iHELP
  The most strategically significant project in their portfolio — combining AI, personalized health monitoring, and cancer research — and the one most likely to define their future collaboration profile.
• ProTego
  Their entry into H2020 participation, demonstrating early commitment to data governance in clinical settings and securing the largest single funding award (€376,875) of their two projects.